Brainstorm Cell Therapeutics (NASDAQ:BCLI) Raised to Hold at StockNews.com

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday.

Brainstorm Cell Therapeutics Stock Performance

Brainstorm Cell Therapeutics stock opened at $1.25 on Wednesday. The stock has a market cap of $7.13 million, a PE ratio of -0.26 and a beta of 0.40. Brainstorm Cell Therapeutics has a one year low of $1.05 and a one year high of $11.89. The stock has a fifty day moving average of $2.42 and a 200 day moving average of $4.62.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is owned by hedge funds and other institutional investors.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.